Washington, D.C. (September 1, 2026) – UsAgainstAlzheimer’s issued the following statement after the federal Advisory Council on Alzheimer’s Research, Care, and Services, established by the National Alzheimer’s Project Act (NAPA), issued recommendations urging congressional passage of bipartisan legislation to advance early detection and diagnosis of Alzheimer’s disease.

“Early detection and diagnosis are critical to changing the trajectory of Alzheimer’s disease. We greatly appreciate that the Advisory Council’s Subcommittee on Risk Reduction has recognized this urgent priority by recommending Congress pass the bipartisan Concentrating on High-Value Alzheimer’s Needs to Get to an End (CHANGE) Act and the Alzheimer’s Screening and Prevention (ASAP) Act. These bills would help more Americans receive timely cognitive assessments and connect them to the care, treatment, and support they need.

“UsAgainstAlzheimer’s has strongly advocated for passage of the bipartisan CHANGE Act, which is led by Representatives LaHood, Sanchez, Bilirakis, and Matsui in the House and Senators Capito and Warner in the Senate. This recommendation represents important momentum toward making early detection a routine part of Medicare. We are hopeful the House Ways and Means Committee will build on this momentum and take action on the CHANGE Act and ASAP Act when Congress returns in September. With new treatments available and continued progress in Alzheimer’s research, Americans cannot afford unnecessary delays in identifying this disease and getting the care they need.”

###

About UsAgainstAlzheimer’s


UsAgainstAlzheimer’s is engaged in a relentless pursuit to end Alzheimer’s, the sixth leading killer in America. Our work centers on prevention, early detection and diagnosis, and equal access to treatments regardless of gender, race, or ethnicity. To achieve our mission, we give voice to patients and caregivers while partnering with government, scientists, the private sector, and allied organizations—the people who put the “Us” in UsAgainstAlzheimer’s.